Equity Overview
Price & Market Data
Price: $10.55
Daily Change: +$0.52 / 4.93%
Range: $9.27 - $11.28
Market Cap: $742,822,016
Volume: 3,941,939
Performance Metrics
1 Week: 19.28%
1 Month: 227.4%
3 Months: 141.3%
6 Months: 19.15%
1 Year: -3.54%
YTD: 31.03%
Company Details
Employees: 427
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.